Related Experiment Video
Updated: Aug 4, 2026
10:10
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Structure-function relationship of 3-phosphoglycerate analogues with platelet aggregation and thromboxane A2
Haemostasis
|January 1, 1987
Summary
Certain phosphoglycerates, including 2,3-diphosphoglycerate (2,3-DPG), 3-phosphoglycerate (3-PG), and 3-phosphoglyceraldehyde (3-PGA), inhibit platelet aggregation and thromboxane B2 (TXB2) formation. These compounds also stimulate aggregation with weak agonists, suggesting a structure-function link.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Platelet aggregation is crucial for hemostasis and thrombosis.
- Thromboxane B2 (TXB2) is a key mediator in platelet activation.
- Understanding the role of specific metabolites in platelet function is important.
Purpose of the Study:
- To investigate the effects of various phosphoglycerates on platelet aggregation.
- To examine the impact of these compounds on thromboxane B2 (TXB2) formation.
- To explore potential structure-function relationships in platelet responses.
Main Methods:
- In vitro study of platelet aggregation.
- Measurement of thromboxane B2 (TXB2) formation.
- Testing various phosphoglycerates (2,3-DPG, 3-PG, 3-PGA, 2-PG, beta-GP) and agonists (norepinephrine, ADP, epinephrine, collagen, Na arachidonate).
Main Results:
- 2,3-diphosphoglycerate (2,3-DPG), 3-phosphoglycerate (3-PG), and 3-phosphoglyceraldehyde (3-PGA) inhibited platelet aggregation and TXB2 formation induced by various agonists.
- These active compounds also induced platelet aggregation and TXB2 formation in the presence of subthreshold Na arachidonate concentrations.
- 2-phosphoglycerate (2-PG) and beta-glycerol phosphate (beta-GP) were found to be inactive.
- A structure-function relationship was observed between 2,3-DPG, 3-PG, 3-PGA, and platelet aggregation/prostaglandin synthesis.
Conclusions:
- Specific phosphoglycerates (2,3-DPG, 3-PG, 3-PGA) modulate platelet aggregation and TXB2 production.
- These findings suggest a direct role for these compounds in regulating platelet function.
- The observed structure-activity relationship highlights the importance of molecular structure in mediating these effects.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...